mTOR signal transduction pathways contribute to TN-C FNIII A1 overexpression by mechanical stress in osteosarcoma cells

Molecules and Cells

Volumn 37, Issue 2, 2014, Pages 118-125

  Zheng, Lianhe ^a   Zhang, Dianzhong ^a   Zhang, Yunfei ^a   Wen, Yanhua ^a   Wang, Yucai ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Mechanical stimulation; MG 63 cells; Osteosarcoma; Tenas cin C; TN C FNIIIA1

Indexed keywords

FIBRONECTIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; TENASCIN; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; S6 KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CELL MIGRATION; CELL MIGRATION ASSAY; FIBRONECTIN TYPE III LIKE REPEAT A1; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MECHANICAL STIMULATION; MECHANICAL STRESS; OSTEOSARCOMA CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OSTEOSARCOMA; PHOSPHOPROTEINS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; STRESS, MECHANICAL; TENASCIN; TOR SERINE-THREONINE KINASES;

EID: 84901407397     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2014.2247     Document Type: Article

References (38)

1. Alves, T.R., da Fonseca, A.C.C., Nunes, S.S., da Silva, A.O., Dubois, L.G.F., Faria, J., Kahn, S.A., Viana, N.B., Marcondes, J., Legrand, C., et al. (2011). Tenascin-C in the extracellular matrix promotes the selection of highly proliferative and tubulogenesis-defective endothelial cells. Exp. Cell Res. 317, 2073-2085.
2. Andrianarivo, A.G., Robinson, J.A., Mann, K.G., and Tracy, R.P. (1992). Growth on type I collagen promotes expression of the osteoblastic phenotype in human osteosarcoma MG-63 cells. J. Cell. Physiol. 153, 256-265.
3. Bielack, S., Carrle, D., Casali, P.G., and Group, O.b.o.t.E.G.W. (2009). Osteosarcoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20, iv137-iv139.
4. Chung, C.Y., and Erickson, H. (1994). Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. J. Cell Biol. 126, 539-548. (Pubitemid 24226269)
5. Ehrlich, P., and Lanyon, L. (2002). Mechanical strain and bone cell function: a review. Osteoporosis Int. 13, 688-700. (Pubitemid 35000996)
6. Feng, X., Zhang, Y., Xu, R., Xie, X., Tao, L., Gao, H., Gao, Y., He, Z., and Wang, H. (2010). Lipopolysaccharide up-regulates the expression of Fcα/μ receptor and promotes the binding of oxidized low-density lipoprotein and its IgM antibody complex to activated human macrophages. Atherosclerosis 208, 396-405.
7. Gill, J., Ahluwalia, M.K., Geller, D., and Gorlick, R. (2012). New targets and approaches in osteosarcoma. Pharmacol. Ther. 137, 89-99.
8. Hirata, E., Arakawa, Y., Shirahata, M., Yamaguchi, M., Kishi, Y., Okada, T., Takahashi, J.A., Matsuda, M., and Hashimoto, N. (2009). Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci. 100, 1451-1459.
9. Jahkola, T., Toivonen, T., Virtanen, I., von Smitten, K., Nordling, S., von Boguslawski, K., Haglund, C., Nevanlinna, H., and Blomqvist, C. (1998). Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br. J. Cancer 78, 1507.
10. Jiang, L., Wei, X., Yi, D., Xu, P., Liu, H., Chang, Q., Yang, S., Li, Z., Gao, H., and Hao, G. (2008). Synergistic effects of cyclic strain and Th1-like cytokines on tenascin-C production by rheumatic aortic valve interstitial cells. Clin. Exp. Immunol. 155, 216-223.
11. Leins, A., Riva, P., Lindstedt, R., Davidoff, M.S., Mehraein, P., and Weis, S. (2003). Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 98, 2430-2439. (Pubitemid 37466658)
12. Lelievre, S., Bisseil, M.J., and Pujuguet, P. (2000). Cell nucleus in context. Crit. Rev. Eukaryot. Gene Exp. 10, 30-37.
13. Li, R., Maminishkis, A., Wang, F.E., and Miller, S.S. (2007). PDGFC and-D induced proliferation/migration of human RPE is abolished by inflammatory cytokines. Invest. Ophthalmol. Vis. Sci. 48, 5722-5732. (Pubitemid 351260877)
14. Lv, Z., Yang, D., Li, J., Hu, M., Luo, M., Zhan, X., Song, P., Liu, C., Bai, H., and Li, B. (2013). Bone morphogenetic protein 9 overexpression reduces osteosarcoma cell migration and invasion. Mol. Cells 36, 119-126.
15. Ma, X.M., and Blenis, J. (2009). Molecular mechanisms of mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol. 10, 307-318.
16. Midwood, K.S., and Orend, G. (2009). The role of tenascin-C in tissue injury and tumorigenesis. J. Cell Commun. Signal. 3, 287-310.
17. Midwood, K.S., Hussenet, T., Langlois, B., and Orend, G. (2011). Advances in tenascin-C biology. Cell. Mol. Life Sci. 68, 3175-3199.
18. Murphy-Ullrich, J.E. (2001). The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J. Clin. Invest. 107, 785-790.
19. Oh, W.J., and Jacinto, E. (2011). mTOR complex 2 signaling and functions. Cell Cycle 10, 2305-2316.
20. Osborne, T., and Khanna, C. (2012). A review of the association between osteosarcoma metastasis and protein translation. J. Comp. Pathol. 146, 132-142.
21. Pazzaglia, L., Conti, A., Chiechi, A., Novello, C., Magagnoli, G., Astolfi, A., Pession, A., Krenacs, T., Alberghini, M., and Picci, P. (2010). Differential gene expression in classic giant cell tumours of bone: tenascin C as biological risk factor for local relapses and metastases. Histopathology 57, 59-72.
22. Ramos, D.M., Chen, B., Regezi, J., Zardi, L., and Pytela, R. (1998). Tenascin-C matrix assembly in oral squamous cell carcinoma. Int. J. Cancer 75, 680-687. (Pubitemid 28145813)
23. Rhee, S.H., Han, I., Lee, M.R., Cho, H.S., Oh, J.H., and Kim, H.S. (2013). Role of integrin-linked kinase in osteosarcoma progression. J. Orthopaedic. Res. 31, 1668-1675.
24. Sage, E., and Bornstein, P. (1991). Extracellular proteins that modulate cell-matrix interactions. SPARC, tenascin, and thrombospondin. J. Biol. Chem. 266, 14831-14834. (Pubitemid 21907577)
25. Saito, Y., Imazeki, H., Miura, S., Yoshimura, T., Okutsu, H., Harada, Y., Ohwaki, T., Nagao, O., Kamiya, S., and Hayashi, R. (2007). A peptide derived from tenascin-C induces β1 integrin activation through syndecan-4. J. Biol. Chem. 282, 34929-34937. (Pubitemid 350232444)
26. Shimoyama, T., Hiraoka, S., Takemoto, M., Koshizaka, M., Tokuyama, H., Tokuyama, T., Watanabe, A., Fujimoto, M., Kawamura, H., and Sato, S. (2010). CCN3 inhibits neointimal hyperplasia through modulation of smooth muscle cell growth and migration. Arterioscler. Thromb. Vasc. Biol. 30, 675-682.
27. Si, Y., Wang, J., Guan, J., Han, Q., and Hui, Y. (2013). Plateletderived growth factor induced alpha-smooth muscle actin expression by human retinal pigment epithelium cell. J. Ocul. Pharmacol. Ther. 29, 310-318.
28. Skelly, D.T., Hennessy, E., Dansereau, M.-A., and Cunningham, C. (2013). A systematic analysis of the peripheral and CNS effects of systemic LPS, IL-1B, TNF-α and IL-6 challenges in C57BL/6 mice. PLoS One 8, e69123.
29. Tamaoki, M., Imanaka-Yoshida, K., Yokoyama, K., Nishioka, T., Inada, H., Hiroe, M., Sakakura, T., and Yoshida, T. (2005). Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am. J. Pathol. 167, 71-80.
30. Tucker, R., Drabikowski, K., Hess, J., Ferralli, J., Chiquet-Ehrismann, R., and Adams, J. (2006). Phylogenetic analysis of the tenascin gene family: evidence of origin early in the chordate lineage. BMC Evol. Biol. 6, 60.
31. Tucker, R.P., and Chiquet-Ehrismann, R. (2009). The regulation of tenascin expression by tissue microenvironments. Biochim. Biophys. Acta 1793, 888-892.
32. Wachtel, M., and Schäfer, B.W. (2010). Targets for cancer therapy in childhood sarcomas. Cancer Treat. Rev. 36, 318-327.
33. Wang, Y., Man, Y., Ding, Y., Ma, B., Qiu, X., Fan, Q., Zheng, L. (2006). Mechanical strain and growth factors regulate expression of tenascin-C by OS cells additively. Oncol. Res. 20, 509-516.
34. Wang, Y., Zheng, L., Ma, B., Zhou, Y., and Fan, Q. (2010). Generation and identification of monoclonal antibodies against FNIII domain D of human tenascin-C. Hybridoma (Larchmt) 29, 13-16.
35. Wu, G., Wang, J., Zhou, Z., Li, T., and Tang, F. (2013). Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: Improvement in the sensitivity or specificity? J. Int. Med. Res. 41, 975-983.
36. Wullschleger, S., Loewith, R., and Hall, M.N. (2006). TOR signaling in growth and metabolism. Cell 124, 471-484. (Pubitemid 43199434)
37. Yuan, T., and Cantley, L. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497-5510.
38. Zhang, Y., and Zheng, X.S. (2012). mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors. Cell Cycle 11, 594-603.